「An oral cancer vaccine using Bifidobacterium vector augments combination of anti-PD-1 and anti-CTLA-4 antibodies in mouse renal cell carcinoma model」の関連論文
-
Metformin enhances the antitumor activity of oncolytic herpes simplex virus HF10 (canerpaturev) in a pancreatic cell cancer subcutaneous model
-
Local, multimodal intralesional therapy renders distant brain metastases susceptible to PD-L1 blockade in a preclinical model of triple-negative breast cancer.
-
A study on the immunostimulatory effects of alarmin HMGN1 in cancer immunity
-
Stromal reaction inhibitor and immune-checkpoint inhibitor combination therapy attenuates excluded-type colorectal cancer in a mouse model
-
Stromal reaction inhibitor and immune-checkpoint inhibitor combination therapy attenuates excluded-type colorectal cancer in a mouse model
-
Research for elucidation of immune evasion mechanisms and development of a novel immunotherapy for cancer in dogs [an abstract of entire text]
-
In situ vaccination using unique TLR9 ligand K3-SPG induces long-lasting systemic immune response and synergizes with systemic and local immunotherapy
-
A novel cancer immunotherapy using tumor-infiltrating B cells in the APC (min/+) mouse model
-
Prognostic significance of plasma interleukin-6/-8 in pancreatic cancer patients receiving chemoimmunotherapy
-
Enhanced anti-tumor effects of the PD-1 blockade combined with a highly absorptive form of curcumin targeting STAT3 (本文)
-
Finding potential synergistic drugs to reduce chemo-resistance for the treatment of highly malignant tumors in female
-
Studies on the Enhancement of Antitumor Effect by Drug Combination in Molecular-Targeted Therapy of Cancer
-
Clinical significance of BIM deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer.
-
Clinical significance of BIM deletion polymorphism on chemoradiotherapy in patients with non-small cell lung cancer.
-
Chemosensitivity of Patient-Derived Cancer Stem Cells Identifies Colorectal Cancer Patients with Potential Benefit from FGFR Inhibitor Therapy
-
The clinical significance of CXCL16 in the treatment of advanced non-small cell lung cancer
-
Gold Nanoparticles Enhance the Tumor Growth-Suppressing Effects of Cetuximab and Radiotherapy in Head and Neck Cancer In Vitro and In Vivo
-
Preclinical evaluation of the efficacy of an antibody to human SIRPα for cancer immunotherapy in humanized mouse models
-
Generation of molecular-targeting peptides for selective inhibition of the interaction between CTLA-4 and B7 in the dog: a new immune checkpoint inhibitor for cancer therapy
-
Significance of PD-L1 expression in carbon-ion radiotherapy for uterine cervical adeno/adenosquamous carcinoma (本文)
-
T-cell response to phytohemagglutinin in the interferon-γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non-small cell lung cancer
-
Oncolytic HSV-1 in combination with lenalidomide for plasma cell neoplasms
-
Metformin Inhibits Proliferation and Tumor Growth of QGP-1 Pancreatic Neuroendocrine Tumor Cells by Inducing Cell Cycle Arrest and Apoptosis
-
Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer
-
Association of CD4-positive cell infiltration with response to vedolizumab in patients with ulcerative colitis
-
Preclinical Evaluation of Lymph Node Targeted Therapy in Mouse Models of Cancer
-
Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non–small cell lung cancer
-
Oncolytic activity of naturally attenuated herpes-simplex virus HF10 against an immunocompetent model of oral carcinoma
-
Characterization of the Anticancer Activities of Some Natural and Synthetic Compounds: Molecular Targets and Mechanism
-
Heat shock protein 105 peptide vaccine could induce antitumor immune reactions in a phase I clinical trial
-
Comprehensive analysis of circulating microRNAs as predictive biomarkers for sorafenib therapy outcome in hepatocellular carcinoma
-
Downregulating vaccinia-related kinase 1 by luteolin suppresses ovarian cancer cell proliferation by activating the p53 signaling pathway
-
Survival Analyses Based on Tumor Microenvironment Profile in Endometrial Carcinoma
-
Design of Novel Targeted Co-delivery System for Combined Chemotherapy and Gene Therapy of Hepatocellular Carcinoma [an abstract of entire text]
-
Aging-associated and CD4 T-cell–dependent ectopic CXCL13 activation predisposes to anti–PD-1 therapy-induced adverse events
-
Evaluating the effect of lenvatinib on sorafenib-resistant hepatocellular carcinoma cells
-
Enhancement of antitumor immune response by radiation therapy combined with dual immune checkpoint inhibitor in a metastatic model of HER2-positive murine tumor
-
Identification of T cell receptors targeting a neoantigen derived from recurrently mutated FGFR3
-
Systemic therapy for salivary gland malignancy: current status and future perspectives
-
Generation of GM-CSF-producing antigen-presenting cells that induce a cytotoxic T cell-mediated antitumor response
-
Placental growth factor is a predictive biomarker for ramucirumab treatment in advanced gastric cancer
-
Studies on Cytotoxic Effects of Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) to Canine Cell Lines Derived from Hemangiosarcoma and Mammary Epithelial Tumor
-
Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy
-
Combined Hypophysitis and Type 1 Diabetes Mellitus Related to Immune Checkpoint Inhibitors
-
Oncolytic herpes simplex virus HF10 (canerpaturev, C-REV) promotes accumulation of CD8^+PD-1^- tumor-infiltrating T cells in PD-L1–enriched tumor microenvironment
-
Activation of BAX and BAK is an attractive combination therapy in melanoma
-
A Review of T-Cell Related Therapy for Osteosarcoma
-
Next Generation Sequencing-Based Transcriptome Predicts Bevacizumab Efficacy in Combination with Temozolomide in Glioblastoma
-
Project 1 Analyzing Tumor Microenvironment and Exploiting its Characteristics in Search of Optimizing Cancer Therapy Including Neutron Capture Therapy (R2P1)
-
B cell depletion with anti-CD20 mAb exacerbates anti-donor CD4+ T cell responses in highly sensitized transplant recipients